I-Mab不足700万美元收购BridgeHealth,斩获CLDN18.2上游权利

CPHI制药在线
Jul 21

关注并星标CPHI制药在线7月17日,全球生物技术公司I-Mab宣布以最高约680万美元的对价全资收购BridgeHealthBiotechCo.,Ltd.(BridgeHealth)。680万美元,尚不足某些ADC药物一次关键临床批次的费用,却锁死了CLDN18.2亲本抗体在双特异、多特异及ADC方向的全部上游权利,为I-Mab的双抗资产givastomig(CLDN18.2×4-1BB)补齐了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10